Abstract
Abstract Introduction: ErbB3 has been identified as a key driver of the PI3K/AKT signaling pathway, resulting in cell growth and survival. MM-121 is a fully human monoclonal antibody targeting ErbB3. By binding to ErbB3, MM-121 blocks heregulin, thereby inhibiting ligand-induced ErbB3 heterodimerization and activation of receptors. Binding of MM-121 also induces downregulation of ErbB3 from the cell surface. Methods: Patients ≥ 18 years with refractory advanced solid tumors were given MM-121 weekly in 4-week cycles at 6 dose levels. Dose escalation was based on dose limiting toxicities (DLTs) during cycle 1. Primary objectives were to determine the maximum tolerated dose (MTD) of MM-121 and describe any objective response and progression free survival. Secondary objectives were to describe the safety, pharmacokinetic (PK), and pharmacodynamic profile of MM-121. A dose expansion cohort at the highest dose cohort was also included for selected tumor types, with required pre- and post-treatment biopsies to assess MM-121 target effects, ErbB3 pathway markers, and guide dose schedule decisions. Results: Between July 2008 to January 2011, 38 patients have been enrolled in the study. Twenty-five patients were enrolled in the dose escalation part of the study and treated until unacceptable toxicity or progression. Six cohorts were completed and an MTD was not reached. Grade 1/2 nausea, diarrhea, fatigue and rash were the most commonly observed adverse events. Grade 1 hypomagnesemia was observed in 4 patients at different doses. One patient experienced a DLT of confusion at the lowest dose, considered possibly related to MM-121 treatment but confounded by other comorbidities. No other treatment related serious AEs were reported. An additional 13 patients have been enrolled to date in an expansion cohort. The overall safety profile for patients in the expansion cohort is similar to that observed for the dose escalation cohorts. Conclusion: In this single agent, first in human, dose escalation phase I study MM-121 was well tolerated with a favorable safety profile. Enrollment in the dose expansion cohort is ongoing. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr LB-410. doi:10.1158/1538-7445.AM2011-LB-410
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.